🚀 VC round data is live in beta, check it out!
TYK Medicines Valuation Multiples
Discover revenue and EBITDA valuation multiples for TYK Medicines and similar public comparables like Shattuck Labs, Esperion Therapeutics, Lyell Immunopharma, Luzhu Biotech and more.
TYK Medicines Overview
About TYK Medicines
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.
Founded
2017
HQ
Employees
153
Website
Sectors
Financials (FY)
EV
$529M
TYK Medicines Financials
TYK Medicines reported last fiscal year revenue of $16K and negative EBITDA of ($51M).
In the same fiscal year, TYK Medicines generated $2K in gross profit, ($51M) in EBITDA losses, and had net loss of ($57M).
Revenue (LTM)
TYK Medicines P&L
In the most recent fiscal year, TYK Medicines reported revenue of $16K and EBITDA of ($51M).
TYK Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $16K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $2K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($51M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (323394%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (296073%) | XXX | XXX | XXX |
| Net Profit | ($43M) | XXX | ($57M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (361640%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TYK Medicines Stock Performance
TYK Medicines has current market cap of $560M, and enterprise value of $529M.
Market Cap Evolution
TYK Medicines' stock price is $1.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $529M | $560M | -1.1% | XXX | XXX | XXX | $-0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTYK Medicines Valuation Multiples
TYK Medicines trades at 33736.3x EV/Revenue multiple, and (10.4x) EV/EBITDA.
TYK Medicines Financial Valuation Multiples
As of April 11, 2026, TYK Medicines has market cap of $560M and EV of $529M.
Equity research analysts estimate TYK Medicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TYK Medicines has a P/E ratio of (12.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $560M | XXX | $560M | XXX | XXX | XXX |
| EV (current) | $529M | XXX | $529M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 33736.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (10.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (11.4x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 257841.4x | XXX | XXX | XXX |
| P/E | (12.9x) | XXX | (9.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TYK Medicines Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TYK Medicines Margins & Growth Rates
TYK Medicines' revenue in the last fiscal year grew by —.
TYK Medicines' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.
TYK Medicines Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (323394%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (0%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 101245% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 220043% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 296086% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TYK Medicines Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shattuck Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Esperion Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lyell Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Luzhu Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Rigel Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TYK Medicines M&A Activity
TYK Medicines acquired XXX companies to date.
Last acquisition by TYK Medicines was on XXXXXXXX, XXXXX. TYK Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TYK Medicines
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTYK Medicines Investment Activity
TYK Medicines invested in XXX companies to date.
TYK Medicines made its latest investment on XXXXXXXX, XXXXX. TYK Medicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TYK Medicines
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TYK Medicines
| When was TYK Medicines founded? | TYK Medicines was founded in 2017. |
| Where is TYK Medicines headquartered? | TYK Medicines is headquartered in China. |
| How many employees does TYK Medicines have? | As of today, TYK Medicines has over 153 employees. |
| Who is the CEO of TYK Medicines? | TYK Medicines' CEO is Yusheng Wu. |
| Is TYK Medicines publicly listed? | Yes, TYK Medicines is a public company listed on HKEX. |
| What is the stock symbol of TYK Medicines? | TYK Medicines trades under 02410 ticker. |
| When did TYK Medicines go public? | TYK Medicines went public in 2024. |
| Who are competitors of TYK Medicines? | TYK Medicines main competitors are Shattuck Labs, Esperion Therapeutics, Lyell Immunopharma, Luzhu Biotech. |
| What is the current market cap of TYK Medicines? | TYK Medicines' current market cap is $560M. |
| What is the current revenue of TYK Medicines? | TYK Medicines' last fiscal year revenue is $16K. |
| What is the current EV/Revenue multiple of TYK Medicines? | Current revenue multiple of TYK Medicines is 33736.3x. |
| Is TYK Medicines profitable? | No, TYK Medicines is not profitable. |
| What is the current net income of TYK Medicines? | TYK Medicines' last 12 months net income is ($43M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.